Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28336711 | 0.75 | PIN1 (0.42) | PIN1TSHRPOLBALDH1A1RECQL | |
| SCHEMBL8483586 | 0.73 | PIN1 (0.53) | PIN1SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL18334414 | 0.73 | NPC1 (0.40) | SMN1; SMN2PTK2BRXFP1TSHRPOLB | |
| Ammonia Solution, Strong SCHEMBL10879989 | 0.71 | PIN1 (0.51) | PIN1SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL2547048 | 0.71 | NPC1 (0.39) | PTK2BTSHRPOLBALDH1A1NPC1 | |
| SCHEMBL28333271 | 0.71 | CA12 (0.42) | PIN1SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL9050955 | 0.71 | PIN1 (0.41) | PIN1SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL4042331 | 0.70 | TSHR (0.67) | PTK2BRXFP1TSHRALDH1A1MEN1 | |
| SCHEMBL1451743 | 0.70 | PIN1 (0.43) | PIN1SMN1; SMN2TSHRPOLBALDH1A1 | |
| SCHEMBL28779829 | 0.69 | PIN1 (0.49) | PIN1SMN1; SMN2TSHRPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| CN-105283177-B | Cyclopropylamine derivatives useful as inhibitors of histone demethylase KDM1A | 欧洲肿瘤研究所有限责任公司 | 2020-07-24 | — | — | CN | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2015-11-05 | — | — | US | disclosed |
| EP-2928457-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | Istituto Europeo di Oncologia S.r.l. (IT) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086790-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2014-06-12 | — | — | WO | disclosed |
| EP-0749428-B1 | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE | PFIZER (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0730588-B1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0344980-A2 | Alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | KDM1A, KDM1B, KDM2A | PIN1 3264/4885SMN1; SMN2 2921/4885PTK2B 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.